Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Dosage Form Proportionality of Eslicarbazepine Acetate
NCT02288312Phase 1Completed
- Sponsor
- BIAL
- Start
- May 2007
- Primary completion
- Jul 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of eslicarbazepine acetate in epilepsy (3 arms), sponsored by BIAL. Primary endpoint: Maximum Plasma Concentration at 72 hours. Started May 2007; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02288312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288312.